Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRO-002 + bevacizumab in advanced ovarian cancer
NCT05200364Phase 1Terminated
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of luveltamab tazevibulin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Sutro Biopharma, Inc. Primary endpoints: Safety and tolerability of STRO-002/bevacizumab as a combination therapy at 24 months and Recommended Phase 2 Dose of STRO-002/bevacizumab at 24 months. Started Mar 2022; status: terminated.
02
Drugs
luveltamab tazevibulin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05200364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200364.